Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism
Authors:
- Nadja S. Sieber-RuckstuhlNSNadja S. Sieber-Ruckstuhl
- Claudia MüllerCMClaudia Müller
- Claudia E. ReuschCRClaudia E. Reusch
- 1 September 2004
- journal article
- research article
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 65 (9) , 1245-1250
Abstract
Objective—To evaluate the effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism (PDH), compare the degree of reduction of aldosterone with that of cortisol, and compare aldosterone concentrations of healthy dogs with those of dogs with PDH. Animals—17 dogs with PDH and 12 healthy dogs. Procedure—For dogs with PDH, the initial dose of trilostane was selected in accordance with body weight. A CBC count, serum biochemical analyses, and ACTH stimulation tests were performed in each dog. Dogs were evaluated 1, 3 to 4, 6 to 8, and 10 to 12 weeks after initiation of treatment. Healthy dogs were evaluated only once. Results—Serum aldosterone concentrations before ACTH stimulation did not change significantly after initiation of treatment with trilostane. At each evaluation after initiation of treatment, serum aldosterone concentrations after ACTH stimulation were significantly lower than corresponding concentrations before initiation of treatment. The overall effect of trilostane on serum aldosterone concentration was less pronounced than the effect on serum cortisol concentration. Median potassium concentrations increased slightly after initiation of treatment with trilostane. Dogs with PDH had significantly higher serum aldo sterone concentrations before and after ACTH stimulation than healthy dogs. Conclusions and Clinical Relevance—Treatment with trilostane resulted in a reduction in serum cortisol and aldosterone concentrations in dogs with PDH, although the decrease for serum aldosterone concentration was smaller than that for serum cortisol concentration. There was no correlation between serum concentrations of aldosterone and potassium during treatment. (Am J Vet Res 2004;65:1245–1250)Keywords
This publication has 25 references indexed in Scilit:
- Congenital Adrenal Hyperplasia due to 3β-Hydroxysteroid Dehydrogenase/ Δ5-Δ4Isomerase DeficiencySeminars in Reproductive Medicine, 2002
- Investigation of the role of aldosterone in hypertension associated with spontaneous pituitary‐dependent hyperadrenocorticism in dogsJournal of Small Animal Practice, 2002
- Effects of estrogens and progestogens on the renin-aldosterone system and blood pressureSteroids, 1996
- Structure of the Human Type II 3β-Hydroxysteroid Dehydrogenase/Δ 5 -Δ 4 Isomerase (3β-HSD) Gene: Adrenal and Gonadal SpecificityDNA and Cell Biology, 1991
- Mitotane (o, p‘-DDD) Treatment of 200 Dogs with Pituitary-Dependent HyperadrenocorticismJournal of Veterinary Internal Medicine, 1991
- Characterization of macaque 3β-hydroxy-5-ene steroid dehydrogenase/Δ5-Δ4 isomerase: structure and expression in steroidogenic and peripheral tissues in primateMolecular and Cellular Endocrinology, 1991
- A Retrospective Study of Aldosterone Secretion in Normal and Adrenopathic DogsJournal of Veterinary Internal Medicine, 1988
- Primary Aldosteronism: Treatment with TrilostaneCardiology, 1985
- EXPERIENCE WITH TRILOSTANE IN THE TREATMENT OF CUSHING'S SYNDROMEClinical Endocrinology, 1983
- An Enzyme in Endocrine Tissues which Oxidizes Δ 5 -3 Hydroxy Steroids to α,β Unsaturated KetonesScience, 1951